← All organizations
Highest phase reached
Phase 3
Timeline
2000s
- Jun 1, 2004
Arrowhead Pharmaceuticals— Founded
2020s
- Nov 18, 2025
plozasiran— Marketing Organization
Drugs by trial phase (27 distinct, 50 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
Indications
Studied for
- alpha 1-Antitrypsin Deficiency
- Carcinoma
- Carcinoma, Renal Cell
- Cystic Fibrosis
- Dyslipidemias
- Fatty Liver
- Fibrosis
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hepatitis D
- Hypercholesterolemia
- Hyperlipoproteinemia Type I
- Hyperlipoproteinemia Type II
- Hypertriglyceridemia
- Non-alcoholic Fatty Liver Disease
- Pulmonary Fibrosis
Marketed drugs (1)
Recent trials (50)
- NCT06796426Lead sponsorN/A—
- NCT07223658Lead sponsorPhase 1/Phase 2Dec 31, 2025
- NCT07241546Lead sponsorPhase 2Dec 31, 2025
- NCT07221344Lead sponsorPhase 1/Phase 2Nov 30, 2025
- NCT07037771Lead sponsorPhase 3Jun 17, 2025
- NCT06937203Lead sponsorPhase 1/Phase 2May 7, 2025
- NCT06880770Lead sponsorPhase 3Apr 24, 2025
- NCT06822790Lead sponsorPhase 3Mar 31, 2025
- NCT06700538Lead sponsorPhase 1Dec 31, 2024
- NCT06672445Lead sponsorPhase 1Nov 30, 2024
- NCT06347016Lead sponsorPhase 3Jul 23, 2024
- NCT06347003Lead sponsorPhase 3Jul 22, 2024
- NCT06347133Lead sponsorPhase 3May 21, 2024
- NCT06209177Lead sponsorPhase 1Apr 22, 2024
- NCT05949294Lead sponsorPhase 1Jan 31, 2024
Details
- Founded
- Pasadena, CA, US Jun 1, 2004
- Last known activity
- Dec 31, 2025